Rezumat articol ediţie STUDIA UNIVERSITATIS BABEŞ-BOLYAI

În partea de jos este prezentat rezumatul articolului selectat. Pentru revenire la cuprinsul ediţiei din care face parte acest articol, se accesează linkul din titlu. Pentru vizualizarea tuturor articolelor din arhivă la care este autor/coautor unul din autorii de mai jos, se accesează linkul din numele autorului.

 
       
         
    STUDIA BIOLOGIA - Ediţia nr.1 din 2021  
         
  Articol:   NOVEL COMBINED THERAPY BASED ON IL-13-PEG-LCL-SIM AND PEG-EV-DOX TO REDUCE MURINE MELANOMA AGGRESIVENESS IN VIVO.

Autori:  GIORGIANA NEGREA, VALENTIN-FLORIAN RAUCA, LAURA PĂTRAȘ, LAVINIA LUPUT, EMILIA LICĂRETE, VLAD-ALEXANDRU TOMA, BOGDAN DUME, ALINA PORFIRE, MANUELA BANCIU, ALINA SESĂRMAN.
 
       
         
  Rezumat:  
Published Online: 2021-06-30
Published Print: 2021-06-30
pp. 13-14

VIEW PDF

FULL PDF

ABSTRACT: Melanoma is one of the most aggressive type of cancer worldwide, which rapidly develops resistance to conventional treatments, resulting in metastasis and recurrence. This study aims to test the potential of IL-13-PEG-LCL-SIM and PEG-EVs-DOX to decrease the aggressiveness of B16.F10 murine melanoma by applying an innovative therapy that targets both tumor-associated-macrophages and cancer cells. Melanoma-bearing mice intravenously received the combined therapy, or the individually formulations of SIM or DOX. In order to detect the level of expression of HIF-1α, a key promoter of hypoxia and of Bcl-xL and Bax, apoptotic proteins, western blot analysis was performed. The concentration of malondialdehyde (MDA) in tumor lysates, a marker of oxidative damage, was assessed by HPLC. Our data showed a strong inhibition of tumor development for the group treated with the combined therapy. Also, there was a substantial decrease of expression of HIF-1α due to PEG-EVs-DOX therapy, which was not noticed in the case of combined therapy. However, the concentration of MDA was highly increased, indicating a disruption of intratumor ROS levels, that alters the balance needed for HIF-1α proper activity. Thus, our findings suggest that the combined active targeted therapy which was tested, strongly inhibits tumor growth. Additional studies must be performed to understand the actions of this new active therapy on other processes which maintain the tumor development, such as angiogenesis and inflammation.

Key words: melanoma, targeted therapy, tumor microenvironment
 
         
     
         
         
      Revenire la pagina precedentă